Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM – Get Free Report)’s share price was down 3% during trading on Thursday . The company traded as low as $19.20 and last traded at $19.25. Approximately 433 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 2,067 shares. The stock had previously closed at $19.84.
Amplify Treatments, Testing and Advancements ETF Stock Down 3.0 %
The firm has a market capitalization of $10.59 million, a PE ratio of 7.10 and a beta of 1.08. The stock has a 50-day moving average price of $18.91 and a 200 day moving average price of $18.48.
Amplify Treatments, Testing and Advancements ETF Company Profile
The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.
Read More
- Five stocks we like better than Amplify Treatments, Testing and Advancements ETF
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- What is the Hang Seng index?
- Parabolic Rise of This Stock Shows No Signs of Slowing
- Find and Profitably Trade Stocks at 52-Week Lows
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for Amplify Treatments Testing and Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Treatments Testing and Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
